Amyloidosis trials in China

In China 38 Also abroad 184

38 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Where
Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
Age
18 years and over
People
12
Run by
Gracell Biotechnologies (Shanghai) Co., Ltd.
See details and how to joinNCT07250269
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Beijing, Binhai, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Liaoning, Nanchang, Nanjing, Shanghai, Shanghaishi, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou, Hefei, Hexi District, Jinan, Nanchang, Nangang, Nanjing, Shenzhen Shi, Taiyuan, Wuhan, Xicheng, Yuanjiagang
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
No phaseTaking people
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Where
Beijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Shaanxi, Shanghai, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Xiamen
Age
18 years to 130 years
People
1,850 worldwide
Run by
AstraZeneca
See details and how to joinNCT06465810
Phase 1/2Not yet taking people in China
[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis
Where
Beijing
Age
18 years and over
People
48
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07835880
Phase 2Taking people
Beta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CA
Where
Beijing
Age
18 years and over
People
60
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07829705
No phaseTaking people
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Where
Beijing
People
2,000
Run by
Peking University First Hospital
See details and how to joinNCT05283993
No phaseTaking people
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Where
Beijing
Age
18 years to 70 years
People
50
Run by
Peking University First Hospital
See details and how to joinNCT07215494
No phaseTaking people
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
Where
Beijing
Age
18 years and over
People
320 worldwide
Run by
AstraZeneca
See details and how to joinNCT07654855
No phaseEnrolling by invitation
Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
Where
Beijing
People
49
Run by
Beijing Anzhen Hospital
See details and how to joinNCT07103863
No phaseTaking people
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Where
Beijing, Changsha, Chengdu, Guangzhou, Wuhan
People
52,121 worldwide
Run by
AstraZeneca
See details and how to joinNCT06355934
No phaseTaking people
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
Where
Hefei, Qingdao, Tianjin
Age
18 years to 80 years
People
500
Run by
Tianjin Medical University
See details and how to joinNCT07130565
No phaseTaking people
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
Where
Hefei, Qingdao, Tianjin
Age
18 years and over
People
25
Run by
Tianjin Medical University
See details and how to joinNCT07232459
Phase 3Not yet taking people in China
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Beijing, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Tianjin, Wuhan, Xi'an
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
Phase 1/2Not yet taking people in China
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
Where
Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Shanghai, Wuhan, Zhengzhou
Age
18 years to 75 years
People
32
Run by
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
See details and how to joinNCT07765524
Phase 2Not yet taking people in China
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07751471
Phase 2Taking people
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Where
Shanghai
Age
18 years and over
People
30
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07638683
Phase 2Taking people
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Where
Beijing, Xi’an
Age
18 years and over
People
39
Run by
Peking University People's Hospital
See details and how to joinNCT07335887
Phase 2Taking people
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
Where
Tianjin
Age
18 years and over
People
21
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07151690
No phaseTaking people
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Where
Beijing, Nanjing, Qingdao, Xi’an
People
41
Run by
Jin Lu, MD
See details and how to joinNCT06192979
Phase 1/2Not yet taking people in China
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
Where
Tianjin
Age
18 years to 70 years
People
50
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07687004
Phase 1/2Taking people
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
Where
Anyang, Baoding, Beijing, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Nanjing, Qingdao, Shanghai, Shenyang, Shenzhen, Tianjin, Xi’an, Zhengzhou
Age
18 years to 80 years
People
70
Run by
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
See details and how to joinNCT07266116
No phaseTaking people
Rapid dFLC Response Predict CHR in AL Amyloidosis
Where
Beijing, Harbin, Nanjing, Shenyang, Xi’an
Age
18 years to 99 years
People
50
Run by
Peking University People's Hospital
See details and how to joinNCT06627309
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
Where
Beijing
Age
18 years and over
People
90
Run by
Sinocelltech Ltd.
See details and how to joinNCT07388602
No phaseTaking people
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
Where
Beijing
People
1,000
Run by
Chinese Academy of Medical Sciences, Fuwai Hospital
See details and how to joinNCT07336394